Novalgina (Metamizole Sodium)

Metamizole Sodium, the active ingredient in Novalgina, is a pyrazolone analgesic presented as an injectable solution for intramuscular and intravenous use. It is employed to manage moderate to severe pain, high fever, postoperative discomfort, and colic in adult patients.

GNH USA supplies Novalgina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Novalgina (metamizole sodium) is used for pain and fever management in several clinical situations, acting as a potent systemic analgesic and antipyretic. - Moderate to severe pain: provides rapid analgesia for acute or chronic painful conditions such as postoperative pain. - High fever: reduces elevated body temperature when conventional antipyretics are insufficient. - Post‑operative pain: offers effective relief during the immediate recovery period after surgery. - Colic: alleviates visceral pain associated with gastrointestinal spasm and colicky conditions. - Acute trauma pain: delivers strong analgesic effect for injuries such as fractures or severe burns.

Metamizole sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort at the site of intramuscular or intravenous administration. - Nausea or vomiting: transient gastrointestinal upset. - Transient hypotension: occasional drop in blood pressure shortly after injection. - Dizziness or headache: mild central nervous system symptoms.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction of white blood cells that can lead to life‑threatening infections. - Anaphylactic reaction: rare but possible severe allergic response requiring immediate medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Metamizole sodium, clinicians should consider several safety precautions to minimize risk. - Assess blood counts: obtain baseline and periodic leukocyte monitoring due to risk of agranulocytosis. - Avoid use in patients with known hypersensitivity to pyrazolones or previous severe reactions. - Use cautiously in renal or hepatic impairment, adjusting dose as clinically indicated. - Do not combine with other myelosuppressive agents without close monitoring. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store below 25°C: keep in the original pack, protect from moisture.

Metamizole sodium can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Cytotoxic chemotherapy agents: increased risk of bone marrow suppression. - Anticoagulants (e.g., warfarin): potential enhancement of bleeding risk. - Other NSAIDs or COX inhibitors: additive gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: possible additive hematologic effects. - ACE inhibitors or diuretics: may potentiate hypotensive episodes. - Lithium: monitor serum levels as NSAID interaction may raise lithium concentration.